CNN — The US Food and Drug Administration granted accelerated approval Friday for the Alzheimer’s disease drug lecanemab, one of the first experimental dementia drugs to appear to slow the progression of cognitive decline. “Alzheimer’s disease immeasurably incapacitates the lives of those who suffer from it and has devastating effects on their loved ones,” Dr. […]

- Tags Accelerated, Alzheimer’s, alzheimer's association, alzheimers disease, approval, brand safety-nsf health issues, brand safety-nsf products and consumers negative, brand safety-nsf sensitive, business, business and industry sectors, chronic diseases, Clinical trials, consumer protection, diseases and disorders, domestic alerts, domestic-business, domestic-health and science, drug, drug and medical devices approval, economy and trade, government health insurance, government organizations - us, health and medical, health care, Health insurance, iab-brain and nervous system disorders, iab-business, iab-business and finance, iab-consumer issues, iab-diseases and conditions, iab-financial assistance, iab-government support and welfare, iab-health insurance, iab-healthcare industry, iab-industries, iab-insurance, iab-non-profit organizations, iab-personal finance, iab-pharmaceutical drugs, iab-pharmaceutical industry, insurance, international alerts, international-business, international-health and science, lecanemab, medical fields and specialties, Medical research, Medicare, neurological disorders and injuries, non-profit and ngo organizations, pharmaceutical industry, Pharmaceuticals, pharmaceuticals and biotechnology regulation and policy, pharmaceuticals and prescription drugs, receives, social assistance and welfare, society, us department of health and human services, us federal departments and agencies, us food and drug administration